FG-M108

DRUG2 trials

Sponsors

FutureGen Biopharmaceutical (Beijing) Co., Ltd

Conditions

Claudin 18.2Pancreatic CancerSolid Tumor Malignancies

Phase 1

A Phase I/II Study of FG-M108 Plus FG-B901 in Advanced CLDN18.2-Positive Solid Tumors

Not yet recruitingNCT07704866

FutureGen Biopharmaceutical (Beijing) Co., LtdClaudin 18.2, Solid Tumor Malignancies

Start: 2026-07-30End: 2029-02-28Target: 120Updated: 2026-07-15

Phase 3

A Study of FG-M108+Chemotherapy vs Placebo+Chemotherapy in Claudin18.2-positive Pancreatic Cancer

Not yet recruitingNCT07383922

FutureGen Biopharmaceutical (Beijing) Co., LtdPancreatic Cancer

Start: 2026-02-28End: 2030-12-31Target: 524Updated: 2026-02-04